Want to see SKYE full AI Analyst Report?
SKYE Stock Chart & Stats
$0.65
-$0.02(-3.42%)
At close: 4:00 PM EDT
$0.65
-$0.02(-3.42%)
Day’s Range― - ―
52-Week Range$0.28 - $4.99
Previous CloseN/A
Volume45.97K
Average Volume (3M)115.36K
Market Cap
$10.84M
Enterprise Value$17.63
Total Cash (Recent Filing)$10.06M
Total Debt (Recent Filing)$35.70K
Price to Earnings (P/E)―
Beta3.19
Next Earnings
Nov 05, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding35,421,413
10 Day Avg. Volume125,555
30 Day Avg. Volume115,358
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.48
Price to Sales (P/S)0.00
P/FCF Ratio-0.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Funding RunwayThe sizable financing package improves near- to medium-term liquidity and supports clinical execution without an immediate need to rely solely on capital markets, giving the combined company time to pursue meaningful development milestones.
Expanded Fibrosis PipelineAdding a Phase 2 lead asset and multiple fibrosis programs could diversify Skye’s development portfolio and concentrate resources in high-unmet-need diseases, creating more opportunities for clinical validation and partnering.
Low Financial LeverageMinimal debt reduces refinancing pressure and fixed cash obligations, allowing more of the company’s available capital to support research and development. This is a relative strength even though the balance sheet remains financially constrained.
Bears Say
Pre-revenue Business ModelWithout commercial revenue, Skye lacks an operating base to absorb development costs, while widening losses indicate increasing dependence on successful clinical outcomes, future financing, licensing, or other external funding.
Sustained Cash BurnPersistent cash consumption directly reduces resources available for trials and operations. Because free cash flow broadly tracks reported losses, the deficit reflects real funding needs that may require additional capital and could pressure strategic flexibility.
Negative Equity And Listing RiskNegative equity weakens the capital cushion and has triggered a Nasdaq compliance process requiring a remediation plan. Restoring compliance may require restructuring or new capital, increasing execution uncertainty and potential dilution.
Skye Bioscience News
SKYE FAQ
What was Skye Bioscience, Inc.’s price range in the past 12 months?
Skye Bioscience, Inc. lowest stock price was $0.28 and its highest was $4.99 in the past 12 months.
What is Skye Bioscience, Inc.’s market cap?
Skye Bioscience, Inc.’s market cap is $10.84M.
When is Skye Bioscience, Inc.’s upcoming earnings report date?
Skye Bioscience, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 76 days.
How were Skye Bioscience, Inc.’s earnings last quarter?
Skye Bioscience, Inc. released its earnings results on Aug 14, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.255 by -$0.015.
Is Skye Bioscience, Inc. overvalued?
According to Wall Street analysts Skye Bioscience, Inc.’s price is currently Overvalued.
Does Skye Bioscience, Inc. pay dividends?
Skye Bioscience, Inc. does not currently pay dividends.
What is Skye Bioscience, Inc.’s EPS estimate?
Skye Bioscience, Inc.’s EPS estimate is -0.21.
How many shares outstanding does Skye Bioscience, Inc. have?
Skye Bioscience, Inc. has 35,421,413 shares outstanding.
What happened to Skye Bioscience, Inc.’s price movement after its last earnings report?
Skye Bioscience, Inc. reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.255. Following the earnings report the stock price went down -7.394%.
Which hedge fund is a major shareholder of Skye Bioscience, Inc.?
Currently, no hedge funds are holding shares in SKYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Technical Analysis
Actinium Pharmaceuticals
―
Outlook Therapeutics
―
Bioxcel Therapeutics
―
Inmune Bio
―
Lantern Pharma
―
Ownership Overview
60.61% Insiders
2.67% Mutual Funds
6.38% Other Institutional Investors
28.21% Public Companies and
Individual Investors